FDA Joint Advisory Committee Votes in Favor of Perrigo’s Opill® Daily Oral Contraceptive for OTC Use

DUBLIN, May 10, 2023 /PRNewswire/ — Perrigo Company plc (NYSE: PRGO), a leading provider of Consumer Self-Care Products, announced today that the U.S. Food and Drug Administration’s (FDA) Nonprescription Drugs Advisory Committee (NDAC) and the Obstetrics, Reproductive, and Urologic Drugs…